@article{ab13fb45651e4584a31b7aeb9e8cd195,
title = "Second cancers in MPN: Survival analysis from an international study: American Journal of Hematology",
abstract = "One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A “poor prognosis” SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a “non-poor prognosis” SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse (1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32; 1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63; 1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti-platelet drugs in modulating patient survival after the occurrence of a SC. {\textcopyright} 2019 Wiley Periodicals, Inc.",
keywords = "acetylsalicylic acid, hydroxyurea, interferon, pipobroman, ruxolitinib, acute leukemia, age, aged, anemia, Article, basal cell carcinoma, breast cancer, cancer diagnosis, cancer prognosis, cancer recurrence, cancer survival, case control study, cause of death, controlled study, digestive system metastasis, drug exposure, esophagus metastasis, female, head and neck metastasis, human, liver metastasis, lung metastasis, lymphoma, major clinical study, male, metastasis, mortality rate, multiple myeloma, myeloproliferative neoplasm, nervous system metastasis, osteosarcoma, ovary metastasis, pancreas metastasis, prediction, priority journal, prostate cancer, survival analysis, thrombosis",
author = "M. Marchetti and A. Ghirardi and A. Masciulli and A. Carobbio and F. Palandri and N. Vianelli and E. Rossi and S. Betti and {Di Veroli}, A. and A. Iurlo and D. Cattaneo and G. Finazzi and M. Bonifacio and L. Scaffidi and A. Patriarca and E. Rumi and I.C. Casetti and C. Stephenson and P. Guglielmelli and E.M. Elli and M. Palova and D. Rapezzi and D. Erez and M. Gomez and K. Wille and M. Perez-Encinas and F. Lunghi and A. Angona and M.L. Fox and E. Beggiato and G. Benevolo and G. Carli and R. Cacciola and M.F. McMullin and A. Tieghi and V. Recasens and S. Isfort and F. Pane and {De Stefano}, V. and M. Griesshammer and A. Alvarez-Larran and A.M. Vannucchi and A. Rambaldi and T. Barbui",
note = "Cited By :1 Export Date: 24 February 2020 CODEN: AJHED Correspondence Address: Barbui, T.; FROM Research Foundation, Papa Giovanni XXIII HospitalItaly; email: tbarbui@fondazionefrom.it Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; hydroxyurea, 127-07-1; pipobroman, 54-91-1; ruxolitinib, 1092939-17-7, 941678-49-5 Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, 5perMille Funding details: Novartis Funding text 1: This study was supported by the FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. The study was also supported by Associazione Italiana per la Ricerca sul Cancro, grant 5perMille, progetto MYNERVA, to PG and AMV. Funding text 2: TB has been a speaker and consultant for Novartis and he has received research grant from AOP Orphan. VDS has received consulting and lecture fees from Amgen, Celgene, Novartis, and institutional research grants from Bayer and Novartis. MLF has been a member of advisory board for Novartis and she has received travel grants from the company. MFM has been a speaker and consultant for Novartis. MM has received honoraria for advisory boards and lectures at sponsored meetings from Celgene, Amgen, Janssen, Gilead, Novartis. AMV has been a speaker for Novartis, Celgene, and Shire and participated to advisory boards of Celgene, Incyte, Novartis. The remaining authors declare that they have no conflict of interest. References: Marchetti, M., Carobbio, A., Capitoni, E., Barbui, T., Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review (2018) Am J Hematol, 93 (5), pp. 698-703; Ghirardi, A., Carobbio, A., Masciulli, A., Barbui, T., Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data (2018) Blood Cancer J, 8 (1), p. 5; Frederiksen, H., Farkas, D.K., Christiansen, C.F., Hasselbalch, H.C., Sorensen, H.T., Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study (2011) Blood, 118 (25), pp. 6515-6520; Landtblom, A.R., Bower, H., Andersson, T.M., Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients (2018) Leukemia, 32 (10), pp. 2203-2210; Chattopadhyay, S., Zheng, G., Sud, A., Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden (2018) Lancet Haematol, 5 (8), pp. e368-e377; Pettersson, H., Knutsen, H., Holmberg, E., Andreasson, B., Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis (2015) Eur J Haematol, 94 (2), pp. 152-156; Barbui, T., Ghirardi, A., Masciulli, A., Second cancer in Philadelphia-negative myeloproliferative neoplasms (MPN-K). A nested case-control study (2019) Leukemia, 33 (8), pp. 1996-2005; Zheng, G., Chattopadyay, S., Sud, A., Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients (2019) Blood Cancer J, 9 (4), p. 40; Donin, N., Filson, C., Drakaki, A., Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008 (2016) Cancer, 122 (19), pp. 3075-3086; Nielsen, C., Birgens, H.S., Nordstgaard, B.G., Kjaer, L., Bojesen, S.E., The JAK2 V617F somatic mutation, mortality and cancer risk in the general population (2011) Haematologica, 96 (3), pp. 450-453; Vannucchi, A.M., Masala, G., Antonioli, E., Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (2009) Cancer Epidemiol Biomarkers Prev, 18 (7), pp. 2068-2073; Li, C., Yin, Z., Wu, W., Genetic variants in TERT-CLPTM1L genetic region associated with several types of cancer: a meta-analysis (2013) Gene, 526 (2), pp. 390-399; J{\"a}ger, R., Harutyunyan, A.S., Rumi, E., Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms (2014) Am J Hematol, 89 (12), pp. 1107-1110; Oddsson, A., Kistinsson, S.Y., Helgason, H., The germline sequence variant rs2736100-C in TERT associates with myeloproliferative neoplasms (2014) Leukemia, 28 (6), pp. 1371-1374; Krahling, T., Balassa, K., Kiss, K.P., Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100 (2016) Cancer Epidemiol Biomarkers Prev, 25 (1), pp. 98-104; (2019), https://seer.cancer.gov/statfacts/html/lungb.html, SEER data; Fogelman, D., Cubillo, A., Garcia-Alfonso, P., Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer (2018) Cancer Med, 7 (11), pp. 5382-5393; Ghermezi, M., Spektor, T.M., Berenson, J.R., The role of JAK inhibitors in multiple myeloma (2019) Clin Adv Hematol Oncol, 17 (9), pp. 500-505; OʼShaughnessy, J., DeMichele, A., Ma, C.X., A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation (2018) Breast Cancer Res Treat, 170 (3), pp. 547-557; Yu, H.A., Perez, L., Chang, W., A phase 1-2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib (2017) J Thorac Oncol, 12 (1), pp. 102-109; Giaccone, G., Sanborn, R.E., Wagar, S.N., A placebo-controlled phase II study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer and systemic inflammation (2018) Clin Lung Cancer, 19 (5), pp. e567-e574; Miller, C.P., Thorpe, J.D., Kortum, A.N., JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors (2014) Cancer Immunol Res, 2 (4), pp. 301-306; Clav{\'e}, S., Pijuan, L., Casadevall, D., Taus, A., CD274(PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients (2018) Histopathology, 72 (2), pp. 259-269; Chen, M., Pockai, B., Andreozzi, M., JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer (2018) Clin Breast Cancer, 18 (5); Ashizawa, T., Iizuka, A., Maeda, C., Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status (2019) Immunol Lett, 19, pp. 30371-30372; Castaneda, C.A., Castillo, M., Aliaga, K., Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies (2019) Biomark Med, 13 (17), pp. 1481-1491; De Stefano, V., Ghirardi, A., Masciulli, A., Frequency of thrombosis is higher in myeloproliferative Ph-neg patients who develop second cancer than in controls (2019) Blood, , (in press); Elwood, P.C., Pickering, J.E., Morgan, G., Systematic review update of observational studies further supports aspirin role in cancer treatment: time to share evidence and decision-making with patients? (2018) PLoS One, 13 (9); Tao, Y., Li, Y., Liu, X., Deng, Q., Yu, Y., Yang, Z., Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis (2018) Cancer Manag Res, 10, pp. 2695-2709",
year = "2019",
month = dec,
day = "9",
doi = "10.1002/ajh.25700",
language = "English",
journal = "Am. J. Hematol.",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
}